Researchers take to space to study cancer drug delivery; Purdue, U.S. Army team up for aneurysm nanotreatment;

 @DamianFierce: Perhaps you can have too much of a good thing. Penn researchers say too many nanocarriers render treatments ineffective. Story | Follow @DamianFierce

> One research team is conducting research on microscale drug delivery for cancer APIs in an uncommon laboratory: the International Space Station. News

> Scientists at the University of Washington and Cornell University have designed three-dimensional, fully functional multivascular networks, allowing for in vitro studies of how drugs interact with vascular systems. Report

> Flexion is celebrating positive Phase IIb results for an intra-articularly delivered osteoarthritis drug, the blockbuster hopeful FX-005. Article

> Purdue and the U.S. Army are working together on nanotechnology-enhanced stents that could treat aneurysms. Story

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.